FN Media Group News Commentary - Breast cancer is an illness in which the breast cells get uncontrollably large. The type of breast cancer depends on which cells in the breast become cancerous. Cancer ...
Novartis and Lilly are national series sponsors for the MORE THAN PINK Walk and Race for the Cure events. Join us at the San Antonio MORE THAN PINK Walk this fall to stand with the community in the ...
Unlike rival CDK 4/6 inhibitor abemaciclib, patients don't need to be lymph-node positive to receive ribociclib after surgery ...
The breast cancer drug Kisqali has received FDA approval to reduce cases of cancer recurrence. The drug was found to reduce ...
The FDA has expanded its approval of Kisqali, a drug already approved to treat advanced breast cancer, to include women with ...
Join us at the Susan G. Komen Bay Area MORE THAN PINK Walk this fall to stand with the community in the fight against breast cancer. Your participation will help raise vital funds, provide crucial ...
2don MSN
Vas Narasimhan, CEO of Novartis, comments on the progress of the firm's Kisqali metastatic breast cancer drug after the ...
Novartis' new data for Kesimpta showed reduced disability progression in relapsing multiple sclerosis patients. Continuous ...
The FDA has approved Kisqali (ribociclib) in adults with HR-positive, HER2-negative stage II and III early breast cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback